Napo Pharmaceuticals: Triple Bottom Line of People, Planet, and Profits (A)

by Kristiana Raube

The Napo Pharmaceuticals case study provides students with an example of a biotech company that has pursued a triple bottom line of people, planet, and profit while making life-saving drugs like crofelemer to deal with diarrhea in adult HIV/AIDS patients and potentially diarrhea for children and other neglected diseases around the world. The case study focuses on CEO and founder, Lisa Conte's challenging road to the point where she and her distribution partners achieved FDA approval for the drug. The case study outlines the issues such mission-oriented biotech companies faced in the more typical profit-oriented world of biotech. Please note: this case also has a supplementary case available. The (B) supplement can be found using product number B5785.

Learning Objectives

To provide students with an example of a pharmaceutical company that has a triple bottom line mission and the challenges such a company faces.


Pub Date: Feb 13, 2014

Discipline: General Management

Subjects: Corporate social entrepreneurship, Health care, Strategic philanthropy, Nonprofit organizations, Entrepreneurship, Venture capital, CEO, Social issues, Society and business relations, Women in business, Partnerships, R&D, Social responsibility

Product #: B5784-PDF-ENG

Industry: Biotechnology

Geography: United States, California, Asia, India

Length: 15 page(s)

Berkeley Haas Case Series
Berkeley Haas Case Series The Berkeley Haas Case Series is a collection of business case studies written by faculty members at the Haas School of Business. Cases are conceived, developed, written, and published throughout the year, on subjects ranging from entrepreneurship and strategy to finance and marketing. Each case includes a teaching note for use in the classroom.


Berkeley Haas Case Series

A new collection of business case studies from Berkeley Haas

The aim of the Berkeley Haas Case Series is to incite business innovation by clarifying disruptive trends and questioning the status quo.

Learn more
Follow Us